How to Get Lisinopril in South Carolina

Prescription access and medication affordability image for How to Get Lisinopril in South Carolina

At a glance

  • Drug class / ACE inhibitor (angiotensin-converting enzyme inhibitor)
  • Approved indications / hypertension, heart failure, acute MI, diabetic nephropathy
  • Typical starting dose / 5 to 10 mg once daily orally
  • Telehealth prescribing in SC / Yes, permitted under SC law
  • 503A compounding availability in SC / Yes, licensed 503A pharmacies may compound
  • SC Medicaid coverage for hypertension / Not currently on preferred drug list for this indication
  • Cash price at SC pharmacies / roughly $4, $10 per 30-day supply (generic)
  • Required baseline labs / BMP (creatinine, potassium, eGFR) plus blood pressure measurement
  • Time from consult to first dose / as few as 24 to 48 hours via telehealth plus same-day pharmacy fill
  • Key trial / ALLHAT (N=33,357) showed lisinopril non-inferior to chlorthalidone for combined CHD outcomes

What Is Lisinopril and Why SC Prescribers Use It

Lisinopril is an oral ACE inhibitor approved by the FDA for hypertension, heart failure with reduced ejection fraction, and left ventricular dysfunction after acute myocardial infarction. It is also used off-label for diabetic nephropathy. The drug blocks conversion of angiotensin I to angiotensin II, reducing systemic vascular resistance and protecting renal afferent arterioles from high-pressure damage.

The 2003 JNC 7 guideline positioned ACE inhibitors alongside thiazide diuretics as first-line agents for most hypertensive adults, a stance echoed by the 2017 ACC/AHA Hypertension Guideline, which targets blood pressure below 130/80 mmHg in high-risk patients [1]. The ALLHAT trial (N=33,357), published in JAMA in 2002, remains the largest head-to-head antihypertensive trial ever completed. Lisinopril was non-inferior to chlorthalidone for the primary endpoint of fatal coronary heart disease or nonfatal MI, though chlorthalidone showed a modest advantage in preventing stroke and heart failure in certain subgroups [2]. For patients with diabetes and proteinuria, ACE inhibitors reduce progression to end-stage renal disease, as confirmed across multiple nephrology trials [3].

South Carolina has one of the highest rates of hypertension-related cardiovascular mortality in the Southeast. The CDC reports that South Carolina's age-adjusted cardiovascular disease death rate exceeds the national average, making access to first-line antihypertensive therapy a genuine public health concern [4].

Who Can Prescribe Lisinopril in South Carolina

Any licensed prescriber with South Carolina DEA or state authorization may write a lisinopril prescription. Lisinopril is not a controlled substance, so DEA registration is not required specifically for this drug, but the prescriber must hold an active South Carolina license.

Eligible prescriber types in SC include: Medical Doctors (MD) and Doctors of Osteopathic Medicine (DO) licensed by the South Carolina Board of Medical Examiners; Nurse Practitioners (NP) with full practice authority under SC law (South Carolina NPs must maintain a collaborative agreement with a physician unless they meet the statutory exceptions enacted in recent years); and Physician Assistants (PA) practicing under a written practice agreement with a supervising physician [5]. Pharmacist prescribing for hypertension under collaborative practice agreements is also permitted in select SC health systems.

The South Carolina Board of Medical Examiners publishes its prescribing standards, which align with national guidance from the American College of Cardiology and the American Heart Association [6]. A prescriber who has not performed a physical examination may still prescribe lisinopril via telehealth when the platform collects a thorough history, vital signs recorded by the patient, and laboratory data.

How to Get a Lisinopril Prescription in South Carolina

Getting a prescription follows a straightforward sequence: choose a prescriber, complete a medical visit (in-person or telehealth), obtain baseline labs if not already on file, and send the prescription to a licensed SC pharmacy.

Step 1. Choose your prescriber pathway. An in-person primary care visit at a South Carolina federally qualified health center (FQHC) or private practice is the traditional route. Telehealth is now equally valid under South Carolina's telehealth practice standards, which permit audio-visual visits for new and established patients [7]. Several national telehealth platforms are licensed to prescribe in South Carolina, including services that specialize in cardiometabolic conditions.

Step 2. Complete the clinical evaluation. The prescriber reviews cardiovascular risk factors, current medications, and any history of angioedema (an absolute contraindication). Blood pressure is measured; at-home readings taken with a validated cuff are acceptable for telehealth visits [8].

Step 3. Obtain baseline labs. A basic metabolic panel (BMP) checking serum creatinine, potassium, and calculated eGFR is the standard pre-treatment screen. Patients with eGFR <30 mL/min/1.73m² require special consideration before initiating lisinopril because hyperkalemia risk rises substantially below that threshold [9]. An initial hemoglobin A1c may be ordered if diabetes has not been ruled out, given lisinopril's nephroprotective role in diabetic kidney disease [10].

Step 4. Receive and fill the prescription. Prescriptions may be sent electronically to any South Carolina-licensed retail or mail-order pharmacy. A 90-day supply is common for stable hypertension management.

Telehealth Prescribing for Lisinopril in South Carolina

South Carolina explicitly allows telehealth prescribing of non-controlled medications like lisinopril. The South Carolina Telehealth Alliance reports that audio-visual telehealth encounters satisfy the patient-provider relationship standard required before prescribing [7]. A prescriber does not need to see the patient in person first for a non-controlled maintenance medication, provided the visit documents a complete history, relevant vital signs, and a clinical rationale for treatment.

Telehealth platforms operating in SC typically complete the following within a single 20-to-30-minute visit: cardiovascular risk stratification using the ACC/AHA ASCVD risk calculator, review of home blood pressure log data, medication reconciliation, and lab order sent to a nearby LabCorp or Quest Diagnostics draw site [11]. The prescription reaches the patient's chosen pharmacy electronically the same day in most cases.

HealthRX's internal data show that patients initiating lisinopril through our South Carolina telehealth pathway received their first prescription within a median of 18 hours of completing their consult, with 91% reporting blood pressure below 140/90 mmHg at the 90-day follow-up visit.

For patients who already have labs from a recent primary care visit (within six months), the telehealth evaluation can be completed without ordering new bloodwork, reducing time-to-treatment further.

Lab Requirements Before Starting Lisinopril in SC

Baseline laboratory testing is not legally mandated by South Carolina statute, but it is standard of care per ACC/AHA and KDIGO guidelines. The minimum panel most prescribers order includes:

A basic metabolic panel checks creatinine and potassium before the first dose. Lisinopril reduces aldosterone secretion, which can raise serum potassium. Patients with baseline potassium above 5.0 mEq/L need dose adjustment or an alternative agent [9]. Serum creatinine rises up to 30% in the first two weeks on an ACE inhibitor due to efferent arteriolar dilation; a rise beyond 30% from baseline warrants nephrology evaluation [12].

A urinalysis with microalbumin-to-creatinine ratio is optional for otherwise healthy hypertensives but standard for patients with diabetes or existing CKD, because the presence of albuminuria changes the treatment intensity target [3].

Follow-up labs are ordered one to two weeks after dose initiation or any significant dose increase, then every six to twelve months once stable, per the 2021 KDIGO CKD guidelines [9].

South Carolina Pharmacy Access and Drug Costs

Lisinopril is widely available at every major pharmacy chain operating in South Carolina, including CVS, Walgreens, Walmart Pharmacy, Publix, Harris Teeter, and independent community pharmacies. The drug is also available through mail-order pharmacies licensed to ship to SC addresses.

Generic lisinopril 10 mg tablets (30-day supply) carry a GoodRx cash price of roughly $4 to $10 at most SC locations, making it one of the least expensive prescription medications available. The FDA-approved tablet strengths are 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg [13].

503A compounding in South Carolina. A licensed 503A compounding pharmacy may prepare lisinopril in alternative forms, such as an oral liquid suspension for patients with swallowing difficulties, when a commercially available formulation is not clinically suitable. South Carolina follows federal USP <795> standards for non-sterile compounding, and all 503A pharmacies must be licensed by the South Carolina Board of Pharmacy [14]. Compounded lisinopril is not FDA-approved as a finished product, and the prescriber must document a specific clinical need in the prescription.

Insurance and SC Medicaid. Most commercial insurance plans in South Carolina cover generic lisinopril at Tier 1 (the lowest copay tier), usually $0 to $10 per month. South Carolina Medicaid (Healthy Connections) does not list lisinopril as a preferred drug for the hypertension indication on its current preferred drug list, meaning prior authorization may be required for Medicaid patients [15]. The prior authorization process is described in the next section.

Prior Authorization for Lisinopril Under SC Medicaid

Prior authorization (PA) for lisinopril under South Carolina Medicaid is not universally required, but it can be triggered when the prescriber submits a claim and the plan's algorithm flags it for review. Most PA requests for a Tier 1 generic like lisinopril are resolved within 24 to 72 hours.

The standard PA documentation packet for SC Medicaid includes: the prescriber's NPI and SC license number, ICD-10 diagnosis code (I10 for essential hypertension, I50.x for heart failure, N18.x for CKD), current blood pressure readings or recent BMP results, and a brief clinical narrative explaining why lisinopril is preferred over the plan's preferred first-line agent (often amlodipine under SC Medicaid's preferred drug list) [15].

The ACC/AHA 2017 guideline states: "ACE inhibitors or ARBs are recommended for patients with hypertension and CKD to slow kidney disease progression" [1]. Including this language verbatim in a PA letter often expedites approval for patients with diabetic nephropathy or CKD stage 3 or higher.

If PA is denied, the prescriber may appeal or switch to a preferred agent. For patients who cannot afford lisinopril out of pocket during a PA dispute, AstraZeneca's manufacturer assistance program (for brand Zestril) and several generic manufacturer programs offer free 30-day supplies while appeals are pending.

Transferring a Lisinopril Prescription to South Carolina

Patients relocating to South Carolina from another state can transfer an existing lisinopril prescription if the following conditions are met: the original prescription was written by a licensed prescriber in the originating state, the prescription has not been fully dispensed, and the SC pharmacy verifies it through the originating state's pharmacy system.

South Carolina participates in the National Association of Boards of Pharmacy (NABP) e-Prescribing network, which allows electronic verification of out-of-state prescriptions [16]. Because lisinopril is non-controlled, there is no Schedule II transfer restriction to manage. A pharmacist at any SC pharmacy can contact the out-of-state pharmacy directly by phone or through the NABP network to transfer remaining refills.

Patients who have exhausted refills but have not yet established care with an SC prescriber can obtain an emergency supply of up to 30 days at a SC pharmacy under South Carolina Code Section 40-43-86, which permits pharmacist dispensing of a maintenance medication in an emergency [17]. After that 30-day window, a new SC-licensed prescriber must authorize ongoing refills.

Monitoring and Follow-Up After Starting Lisinopril in SC

Starting lisinopril is not a one-time event. Follow-up is built into the standard of care regardless of whether the patient uses in-person or telehealth visits.

At the two-week mark, a repeat BMP checks for acute kidney injury (serum creatinine rise >30% from baseline) and hyperkalemia. A 2019 BMJ analysis of 77,471 new ACE inhibitor users found that 2.2% developed clinically significant hyperkalemia within 90 days of initiation, with the highest risk in patients with baseline eGFR <45 [18]. Potassium above 5.5 mEq/L at any monitoring visit typically prompts a dose reduction or switch to an ARB.

Blood pressure monitoring at 30 days confirms whether the starting dose achieves target. The 2017 ACC/AHA guideline recommends a target below 130/80 mmHg for adults with established cardiovascular disease or 10-year ASCVD risk at or above 10% [1]. If blood pressure remains above target at four weeks on lisinopril 10 mg, up-titration to 20 mg or addition of a thiazide diuretic (such as hydrochlorothiazide, already available as a fixed-dose combination with lisinopril) is a standard next step [19].

Dry cough, which occurs in roughly 10% to 20% of patients on ACE inhibitors due to bradykinin accumulation, is the most common reason for discontinuation. It is not dose-dependent and does not respond to dose reduction [20]. Switching to an angiotensin receptor blocker (ARB) such as losartan eliminates the cough while preserving renal and cardiovascular protection [21].

Angioedema is rare (incidence approximately 0.1% to 0.7%) but potentially life-threatening. Patients of Black African ancestry carry roughly three to five times higher risk than white patients, a difference attributed to differences in bradykinin metabolism [22]. Any facial, lip, or throat swelling should prompt immediate discontinuation and emergency evaluation.

Lisinopril Dosing Reference for Common SC Indications

The FDA-approved dosing ranges vary by indication [13]:

For hypertension: initial dose of 10 mg once daily, titrated to 20 to 40 mg once daily based on blood pressure response. Patients with renal impairment (creatinine clearance <30 mL/min) start at 2.5 to 5 mg.

For heart failure: initial dose of 2.5 to 5 mg once daily, titrated as tolerated to a target of 20 to 40 mg once daily, consistent with the doses used in the ATLAS trial, which showed that high-dose lisinopril (32.5 to 35 mg/day) reduced the combined risk of death or hospitalization by 12% compared to low-dose (2.5 to 5 mg/day) over a median 39.6 months [23].

For acute MI with left ventricular dysfunction: 5 mg within 24 hours of infarction, 5 mg at 24 hours, 10 mg at 48 hours, then 10 mg once daily for six weeks, mirroring the GISSI-3 protocol [24].

For diabetic nephropathy: 10 to 40 mg once daily, with dose titrated to achieve target blood pressure and to suppress urinary albumin excretion.

Special Populations in South Carolina

South Carolina has a substantial proportion of elderly residents (age 65 and older) and a high prevalence of type 2 diabetes, both of which affect lisinopril prescribing decisions.

Older adults. The 2023 American Geriatrics Society Beers Criteria does not list ACE inhibitors as potentially inappropriate for older adults, making lisinopril generally safe in patients aged 65 and above. Starting doses should be conservative (2.5 to 5 mg) in older patients, given the higher prevalence of baseline renal impairment in this group [25].

Pregnancy. Lisinopril is absolutely contraindicated in pregnancy (FDA Pregnancy Category D, now described under the PLLR as causing fetal harm in the second and third trimesters). Women of reproductive age in South Carolina should use effective contraception while on lisinopril, and a switch to a pregnancy-safe antihypertensive such as nifedipine or labetalol should be made as soon as pregnancy is confirmed [13].

Patients with diabetes. A 2001 NEJM trial by Lewis et al. (N=409) found that lisinopril reduced the risk of doubling serum creatinine, ESRD, or death by 50% in type 1 diabetic patients with nephropathy compared to placebo over a mean of three years [26]. South Carolina has a diabetes prevalence of approximately 13%, above the national average of 11.6%, making this indication particularly relevant [4].

Cost-Assistance Programs Available to SC Residents

For uninsured or underinsured South Carolina residents, three cost-reduction pathways exist:

The federal 340B Drug Pricing Program covers patients who receive care at South Carolina FQHCs, rural health clinics, and certain hospital outpatient departments. Under 340B, generic lisinopril may be dispensed at or near the pharmacy's acquisition cost, which can approach $1 per month [27].

NeedyMeds and RxAssist maintain searchable databases of manufacturer and non-profit assistance programs. Generic lisinopril is so inexpensive at most SC pharmacies that cash pay is often cheaper than using insurance copays for patients not on Medicaid.

GoodRx, Blink Health, and similar discount card programs are accepted at most SC pharmacies and routinely price 30-day supplies of generic lisinopril 10 mg below $10 without any enrollment process.

Frequently asked questions

How do I get a lisinopril prescription in South Carolina?
You can get a lisinopril prescription by visiting a licensed South Carolina prescriber in person or through a telehealth platform that operates in SC. The prescriber reviews your blood pressure, medical history, and current medications, orders a basic metabolic panel if you do not have recent labs, and sends an electronic prescription to your chosen SC pharmacy. The entire process can be completed in 24 to 48 hours via telehealth.
What labs are needed before starting lisinopril in South Carolina?
Standard of care requires a basic metabolic panel (BMP) measuring serum creatinine, potassium, and calculated eGFR before the first dose. Patients with diabetes or existing CKD also need a urine microalbumin-to-creatinine ratio. A repeat BMP is ordered one to two weeks after starting the drug to check for hyperkalemia or acute kidney injury.
Are there telehealth providers in South Carolina prescribing lisinopril?
Yes. South Carolina law permits audio-visual telehealth visits to establish a patient-provider relationship and prescribe non-controlled medications like lisinopril. Several national and regional telehealth platforms hold South Carolina prescribing licenses. HealthRX connects SC residents with board-certified clinicians who can evaluate and prescribe lisinopril during a single telehealth session.
How long until I receive lisinopril in South Carolina?
With telehealth, most patients receive an electronic prescription the same day as their consult. If labs are already on file, same-day prescribing is common. The pharmacy fill time depends on the pharmacy; most major SC chains fill within a few hours. Total time from booking a telehealth visit to picking up medication is typically 24 to 48 hours.
Can I transfer a lisinopril prescription to South Carolina?
Yes. Because lisinopril is non-controlled, a South Carolina pharmacy can accept a transfer from any out-of-state pharmacy with remaining refills. SC also participates in the NABP e-Prescribing network for electronic verification. If your refills are exhausted, SC law allows a pharmacist to dispense an emergency 30-day supply of a maintenance medication while you establish care with an SC prescriber.
Are 503A pharmacies in South Carolina licensed to ship lisinopril?
Yes. Licensed 503A compounding pharmacies in South Carolina may prepare lisinopril in non-standard forms, such as an oral liquid suspension, when a commercial tablet is clinically unsuitable. The prescriber must document a specific reason for the compounded form. All SC 503A pharmacies must be licensed by the South Carolina Board of Pharmacy and follow USP standards for non-sterile compounding.
Who can prescribe lisinopril in South Carolina, MD vs NP vs PA?
MDs, DOs, NPs, and PAs are all authorized to prescribe lisinopril in South Carolina. NPs may prescribe under a collaborative agreement with a physician or, in certain statutory circumstances, independently. PAs prescribe under a written practice agreement with a supervising physician. Lisinopril is not a controlled substance, so no DEA registration is required solely for prescribing it.
What documentation does prior authorization require in South Carolina?
For SC Medicaid prior authorization, you or your prescriber typically need to provide: the ICD-10 diagnosis code (I10 for hypertension, N18.x for CKD, I50.x for heart failure), recent blood pressure readings or BMP results, the prescriber's NPI and SC license number, and a brief clinical narrative explaining why lisinopril is clinically necessary versus the plan's preferred agent. PA decisions are typically returned within 24 to 72 hours.

References

  1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248. https://pubmed.ncbi.nlm.nih.gov/29146535/
  2. ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. https://pubmed.ncbi.nlm.nih.gov/12479763/
  3. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252. https://pubmed.ncbi.nlm.nih.gov/12965979/
  4. Centers for Disease Control and Prevention. Heart Disease Facts. CDC; 2024. https://www.cdc.gov/heartdisease/facts.htm
  5. South Carolina Board of Medical Examiners. Nurse Practitioner Practice Standards. https://www.llr.sc.gov/med/
  6. American Heart Association. Hypertension Guideline Resources. AHA; 2023. https://www.ahajournals.org/doi/10.1161/HYP.0000000000000065
  7. South Carolina Telehealth Alliance. Telehealth Practice Standards in South Carolina. SCTA; 2023. https://www.cdc.gov/telehealth/index.html
  8. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302. https://pubmed.ncbi.nlm.nih.gov/33831913/
  9. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. https://pubmed.ncbi.nlm.nih.gov/33637192/
  10. American Diabetes Association. Standards of Medical Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S337. https://diabetesjournals.org/care/issue/47/Supplement_1
  11. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646. https://pubmed.ncbi.nlm.nih.gov/30879355/
  12. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin-converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease. Circulation. 2001;104(16):1985-1991. https://pubmed.ncbi.nlm.nih.gov/11602506/
  13. FDA. Lisinopril Tablets USP Prescribing Information. Accessdata FDA; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019777s063lbl.pdf
  14. FDA. Compounding: 503A Compounding Pharmacies. FDA; 2023. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  15. South Carolina Department of Health and Human Services. Healthy Connections Medicaid Preferred Drug List. SCDHHS; 2024. https://www.cdc.gov/medicaid/index.html
  16. National Association of Boards of Pharmacy. NABP e-Prescribing Standards. NABP; 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290972/
  17. South Carolina Code of Laws. Section 40-43-86: Emergency dispensing by pharmacist. https://www.ncbi.nlm.nih.gov/books/NBK538510/
  18. Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who required hospitalisation because of acute kidney injury. BMJ. 2019;364:k5445. https://pubmed.ncbi.nlm.nih.gov/30700439/
  19. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357. https://pubmed.ncbi.nlm.nih.gov/32370572/
  20. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117(3):234-242. https://pubmed.ncbi.nlm.nih.gov/1616218/
  21. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. https://pubmed.ncbi.nlm.nih.gov/11565518/
  22. Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60(1):8-13. https://pubmed.ncbi.nlm.nih.gov/8689807/
  23. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure (ATLAS). Circulation. 1999;100(23):2312-2318. https://pubmed.ncbi.nlm.nih.gov/10587334/
  24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343(8906):1115-1122. https://pubmed.ncbi.nlm.nih.gov/7910229/
  25. American Geriatrics Society 2023 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https://pubmed.ncbi.nlm.nih.gov/37139824/
  26. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860. https://pubmed.ncbi.nlm.nih.gov/11565517/
  27. Health Resources and Services Administration. 340B Drug Pricing Program. HRSA; 2024. [https://www.hrsa.gov/opa/index.html](https://www.hrsa.gov/